Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Innovent Approved to Start US Clinical Trial of CD47 Immunotherapy

publication date: Oct 1, 2018

Innovent Biologics of Suzhou reported that its IND application for IBI-188, a fully human anti-CD47 mAb drug candidate, has been approved to start US clinical trials in patients with advanced malignancies and lymphomas. Last month, China approved clinical trials for the same candidate. The candidate is Innovent's second molecule approved for US trials. The other, also an immunotherapy, is an anti-PD-1 antibody. Innovent is the first Chinese biopharma to be granted clinical trial approval for an anti-CD47 immunotherapy from the US FDA. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital